FrancophonIA/ELRC3.0 huggingface dataset:
English: Talk to your doctor, pharmacist or nurse before using Tremfya:
Danish: Kontakt lægen, apotekspersonalet eller sundhedspersonalet, før du bruger Tremfya:
English: In two phase III clinical studies through Week 48, 0.7% of Tremfya injections and 0.3% of placebo injections were associated with injection site reactions.
Danish: I perioden til og med uge 48 i to kliniske fase III-studier var 0,7 % af injektionerne af Tremfya og 0,3 % af injektionerne af placebo forbundet med reaktioner på injektionsstedet.
English: Do not use the pre-filled pen if it is dropped after removing the cap.
Danish: Undlad at bruge den fyldte pen, hvis den har været tabt, efter at hætten er fjernet.
English: These results are consistent with the clinical benefit observed with guselkumab treatment in plaque psoriasis.
Danish: Disse resultater stemmer overens med den kliniske fordel, der er observeret ved behandling af plaque-psoriasis med guselkumab.
English: No mutagenicity or carcinogenicity studies were conducted with guselkumab.
Danish: Der er ikke udført mutagenicitets- eller karcinogenicitetsstudier med guselkumab.
English: No specific study has been conducted to determine the effect of renal or hepatic impairment on the pharmacokinetics of guselkumab.
Danish: Der er ikke udført et specifikt studie for at fastlægge virkningen af nedsat nyre- eller leverfunktion på guselkumabs farmakokinetik.
English: What Tremfya contains - The active substance is guselkumab.
Danish: Tremfya indeholder: - Aktivt stof: guselkumab.
English: Single intravenous doses of guselkumab up to 987 mg (10 mg/kg) have been administered in healthy volunteers and single subcutaneous doses of guselkumab up to 300 mg have been administered in patients with plaque psoriasis in clinical studies without dose-limiting toxicity.
Danish: Intravenøse enkeltdoser af guselkumab på op til 987 mg (10 mg/kg) er blevet administreret til raske frivillige, og en enkelt subkutan dosis af guselkumab på op til 300 mg er blevet administreret til patienter med plaque-psoriasis i kliniske studier uden dosisbegrænsende toksicitet.
English: Serious allergic reactions, which can include symptoms of hives and shortness of breath, have occurred with Tremfya (see “Serious side effects” in section 4).
Danish: Alvorlige allergiske reaktioner, som kan inkludere symptomer på nældefeber eller kortåndethed er forekommet med Tremfya (se pkt.
English: Each Tremfya pack is provided with an ‘Instructions for use' leaflet that fully describes the preparation and administration of the pre-filled syringe or pre-filled pen.
Danish: Hver pakning med Tremfya har en „Brugsanvisning“, som i detaljer beskriver klargøring og administration af den fyldte injektionssprøjte eller den fyldte pen.
English: • if you recently had or are due to have a vaccination.
Danish: • hvis du er blevet vaccineret for nylig eller snart skal vaccineres.
English: Guselkumab is a fully human immunoglobulin G1 lamda (IgG1λ) monoclonal antibody (mAb) to the interleukin (IL)-23 protein, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology.
Danish: Guselkumab er et fuldt humant immunoglobulin G1-lamda (IgG1λ) monoklonalt antistof (mAb) mod proteinet interleukin (IL)-23, som fremstilles i ovarieceller fra kinesiske hamstere (CHO) vha. rekombinant DNA-teknologi.
English: Patients treated with Tremfya should be instructed to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur.
Danish: Patienter i behandling med Tremfya skal have besked på at søge læge, hvis der opstår tegn eller symptomer på klinisk betydningsfuld kronisk eller akut infektion.
English: Please read these Instructions for use before using the Tremfya pre-filled pen and each time you get a new pre-filled pen.
Danish: Læs denne brugsanvisning, før du bruger Tremfya fyldt pen, og hver gang du får en ny pen.
English: Treatment with Tremfya should not be initiated in patients with any clinically important active infection until the infection resolves or is adequately treated.
Danish: Der må ikke påbegyndes behandling med Tremfya hos patienter med en klinisk betydningsfuld aktiv infektion, før infektionen har fortaget sig eller er passende behandlet.
English: In in vitro models, guselkumab was shown to inhibit the bioactivity of IL-23 by blocking its interaction with cell surface IL-23 receptor, disrupting IL-23-mediated signaling, activation and cytokine cascades.
Danish: I in vitro-modeller blev det påvist, at guselkumab hæmmer bioaktiviteten af IL-23 ved at blokere dets interaktion med IL-23receptorer på celleoverfladen, hvilket forstyrrer IL-23-medieret signal-, aktiverings- og cytokinkaskader.
English: In a Phase 1 study in subjects with moderate to severe plaque psoriasis, changes in systemic exposures (Cmax and AUCinf) of midazolam, S-warfarin, omeprazole, dextromethorphan, and caffeine after a single dose of guselkumab were not clinically relevant, indicating that drug interactions between guselkumab and substrates of various CYP enzymes (CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2) are unlikely.
Danish: I et fase 1-studie hos forsøgspersoner med moderat til svær plaque-psoriasis var ændringer i systemisk eksponering (Cmax og AUCinf) for midazolam, S-warfarin, omeprazol, dextromethorphan og koffein efter en enkelt dosis af guselkumab ikke klinisk relevante, hvilket tyder på ringe sandsynlighed for lægemiddelinteraktion mellem guselkumab og substrater for forskellige CYP-enzymer (CYP3A4, CYP2C9, CYP2C19, CYP2D6 og CYP1A2).
English: Loss of PASI 90 response was noted as early as 4 weeks after withdrawal of guselkumab treatment with a median time to loss of PASI 90 response of approximately 15 weeks.
Danish: Tab af PASI 90-respons blev set så tidligt som 4 uger efter seponering af behandling med guselkumab med en median tid til tab af PASI 90-respons på ca. 15 uger.
English: You and your doctor should decide if you will breast-feed or use Tremfya.
Danish: Sammen med din læge skal du beslutte, om du skal amme eller bruge Tremfya.
English: Includes only subjects with ss-IGA, f-PGA, hf-PGA score ≥ 2 at baseline or baseline NAPSI score > 0.
Danish: Omfatter kun forsøgspersoner med ss-IGA-, f-PGA- eller hf-PGA-score ≥ 2 ved baseline eller NAPSI-score ved baseline > 0.
English: The efficacy and safety of guselkumab was demonstrated regardless of age, gender, race, body weight, plaques location, PASI baseline severity, concurrent psoriatic arthritis, and previous treatment with a biologic therapy.
Danish: Virkningen og sikkerheden af guselkumab blev påvist uanset alder, køn, race, legemsvægt, placering af plaques, PASI-sværhedsgrad ved baseline, samtidig psoriasisartrit og tidligere behandling med et biologisk lægemiddel.
English: The solution should be clear, colourless to light yellow, and may contain a few small white or clear particles.
Danish: Opløsningen skal være klar, farveløs til let gul og kan indeholde nogle få små hvide eller gennemsigtige partikler.
English: Safety guard
Danish: Sikkerhedsanordning
English: All patients (N=871) received open-label ustekinumab (45 mg ≤100 kg and 90 mg >100 kg) at Weeks 0 and 4.
Danish: Alle patienter (n = 871) fik ikke-blindet ustekinumab (45 mg ≤100 kg og 90 mg >100 kg) i uge 0 og 4.
English: Check the expiration date (‘EXP') on the carton.
Danish: Kontrollér udløbsdatoen (‘EXP') på kartonen.
English: Mean half-life (T1/2) of guselkumab was approximately 17 days in healthy subjects and approximately 15 to 18 days in patients with plaque psoriasis across studies.
Danish: Den gennemsnitlige halveringstid (T1/2) for guselkumab var ca. 17 dage hos raske forsøgspersoner og ca. 15 til 18 dage hos patienter med plaque-psoriasis på tværs af studierne.
English: Do not rub the injection site.
Danish: Undlad at gnide på injektionsstedet.
English: If you forget to use Tremfya If you have forgotten to inject a dose of Tremfya, inform your doctor.
Danish: Hvis du har glemt at bruge Tremfya Fortæl det til lægen, hvis du har glemt at injicere en dosis af Tremfya.
English: Some side effects are uncommon (may affect up to 1 in 100 people): - pain at the injection site - allergic reaction - skin rash
Danish: Nogle bivirkninger er ikke almindelige (kan forekomme hos op til 1 ud af 100 patienter): - smerter på injektionsstedet - allergisk reaktion - hududslæt
English: Among patients who were withdrawn from treatment and subsequently re-initiated guselkumab, 80% regained a PASI 90 response when assessed 20 weeks after initiation of retreatment.
Danish: Blandt de patienter, for hvem behandlingen blev seponeret, og som efterfølgende genoptog behandling med guselkumab, havde 80 % genvundet et PASI 90-respons ved vurdering 20 uger efter genoptagelse af behandlingen.
English: The Tremfya pre-filled syringe is intended for injection under the skin, not into the muscle or vein.
Danish: Tremfya fyldt injektionssprøjte er beregnet til injektion under huden, ikke i en muskel eller blodåre.
English: IGA 0/1
Danish: PASI 100 IGA 0/1
English: If you stop using Tremfya
Danish: Hvis du holder op med at bruge Tremfya
English: Differences in response rates between guselkumab and ustekinumab treated patients were noted as early as 4 weeks after randomisation (11.1% and 9.0%, respectively) and reached a maximum 24 weeks after randomisation (see Figure 3).
Danish: Forskelle i responsrater mellem patienter, der blev behandlet med henholdsvis guselkumab og ustekinumab, blev set allerede 4 uger efter randomisering (henholdsvis 11,1 % og 9,0 %), og de nåede maksimum 24 uger efter randomisering (se figur 3).
English: Between 12 and 24 weeks after randomisation, guselkumab patients achieved an IGA score 0/1 with ≥ 2 grade improvement twice as often as ustekinumab patients (mean 1.5 vs 0.7 visits, respectively, p < 0.001).
Danish: Mellem 12 og 24 uger efter randomisering opnåede guselkumab-patienterne en IGA-score 0/1 med ≥ 2 graders forbedring dobbelt så hyppigt som ustekinumab-patienterne (middeltal henholdsvis 1,5 versus 0,7 besøg, p < 0,001).
English: Sign score = 0, n (%)
Danish: Tegn-score = 0, n (%)
English: Tremfya should not be used if the solution is cloudy or discoloured, or contains large particles.
Danish: Tremfya må ikke bruges, hvis opløsningen er uklar eller misfarvet, eller hvis den indeholder store partikler.
English: Guselkumab is a human IgG1λ monoclonal antibody (mAb) that binds selectively to the interleukin 23 (IL-23) protein with high specificity and affinity.
Danish: Guselkumab er et humant monoklonalt IgG1λ-antistof (mAb), som binder selektivt til proteinet IL-23 (interleukin 23) med høj specificitet og affinitet.
English: Baseline disease characteristics were consistent with a population of moderate to severe plaque psoriasis with a median BSA of 20%, a median PASI score of 18, and an IGA score of severe for 24% of patients.
Danish: Sygdomskarakteristika ved baseline svarede til en population med moderat til svær plaque-psoriasis med et mediant BSA på 20 %, en median PASI-score på 18 og en IGA-score på svær for 24 % af patienterne.
English: In VOYAGE 2, guselkumab patients had significantly greater improvement from baseline compared to placebo in health-related quality of life, anxiety and depression, and work limitation measures at Week 16, as measured by the 36-item Short Form (SF-36) health survey questionnaire, Hospital Anxiety and Depression Scale (HADS), and Work Limitations Questionnaire (WLQ), respectively.
Danish: I VOYAGE 2 havde guselkumab-patienter signifikant større forbedring fra baseline sammenlignet med placebo i helbredsrelateret livskvalitet, angst og depression samt begrænsninger vedrørende erhvervsevne i uge 16 målt ved henholdsvis helbredsspørgeskemaet SF-36 (36-item Short Form), HADS (Hospital Anxiety and Depression Scale) og WLQ (Work Limitations Questionnaire).
English: In a phase I study, treatment with guselkumab resulted in reduced expression of IL-23/Th17 pathway genes and psoriasis-associated gene expression profiles, as shown by analyses of mRNA obtained from lesional skin biopsies of patients with plaque psoriasis at Week 12 compared to baseline.
Danish: I et fase I-studie resulterede behandling med guselkumab i reduceret ekspression af IL-23/Th17-gener og psoriasis-forbundne genekspressionsprofiler, påvist ved analyser af mRNA indhentet fra biopsier af aktive plaques fra patienter med plaque-psoriasis i uge 12 sammenlignet med baseline.
English: Tremfya is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.
Danish: Tremfya er indiceret til behandling af moderat til svær plaque-psoriasis hos voksne, som er kandidater til systemisk behandling.
English: Change from baseline, mean (standard deviation)
Danish: Ændring fra baseline, gennemsnit (standardafvigelse) Uge 16
English: Do not use this medicine after the expiry date which is stated on the pre-filled pen label and on the outer carton after “EXP”.
Danish: Brug ikke lægemidlet efter den udløbsdato, der står på den fyldte pens etiket og på den ydre karton efter „EXP“.
English: In pooled phase III analyses, approximately 9% of patients treated with Tremfya developed antidrug antibodies in up to 156 weeks of treatment.
Danish: I puljede fase III-analyser udviklede cirka 9 % af de patienter, der blev behandlet med Tremfya, antistoffer mod lægemidlet i løbet af op til 156 ugers behandling.
English: Some side effects are common (may affect up to 1 in 10 people): - headache - joint pain (arthralgia) - diarrhoea - stomach flu (gastroenteritis) - redness at the injection site - hives - fungal infection of the skin, for instance between the toes (e.g., athlete's foot) - herpes simplex infections
Danish: Nogle bivirkninger er almindelige (kan forekomme hos op til 1 ud af 10 patienter): - hovedpine - ledsmerter (artralgi) - diarré - maveinfluenza (gastroenteritis) - rødme på injektionsstedet - nældefeber - svampeinfektion i huden, for eksempel mellem tæerne (f.eks. fodsvamp) - forkølelsessår (herpes simplex)
English: Do not use this medicine after the expiry date which is stated on the syringe label and on the outer carton after “EXP”.
Danish: Brug ikke lægemidlet efter den udløbsdato, der står på injektionssprøjtens etiket og på den ydre karton efter „EXP“.
English: Tremfya is used to treat adults with moderate to severe “plaque psoriasis”, an inflammatory condition affecting the skin and nails.
Danish: Tremfya anvendes til behandling af voksne med moderat til svær „plaque-psoriasis“, som er en betændelsessygdom i huden og neglene.
English: Check the liquid in the window.
Danish: Kontrollér væsken i vinduet.
English: Number of patients (%) Guselkumab (N=534)
Danish: Antal patienter (%) Guselkumab (N = 534)
English: Guselkumab exerts clinical effects in plaque psoriasis through blockade of the IL-23 cytokine pathway.
Danish: Guselkumabs kliniske virkning på plaque-psoriasis sker gennem blokade af IL-23-cytokinet.
English: In VOYAGE 2, 88.6% of patients receiving guselkumab maintenance treatment at Week 48 were PASI 90 responders compared to 36.8% of patients who were withdrawn from treatment at Week 28 (p < 0.001).
Danish: I VOYAGE 2 var 88,6 % af de patienter, der fik guselkumab som vedligeholdelsesbehandling, PASI 90-respondere i uger 48 sammenlignet med 36,8 % af de patienter, der fik behandlingen seponeret i uge 28 (p < 0,001).
English: The pre-filled syringe or pre-filled pen should not be shaken.
Danish: Den fyldte injektionssprøjte eller den fyldte pen må ikke omrystes.
English: Signs of infections may include fever or flu like symptoms; muscle aches; cough; shortness of breath; burning when you urinate or urinating more often than usual; blood in your phlegm (mucus); weight loss; diarrhoea or stomach pain; warm, red, or painful skin or sores on your body which are different from your psoriasis.
Danish: Tegn på infektioner kan inkludere feber eller influenzalignende symptomer, ømme muskler, hoste, kortåndethed, en brændende fornemmelse ved vandladning eller hyppigere vandladning end sædvanligt, blodigt slim, vægttab, diarré eller mavesmerter, varm, rød eller smertende hud eller sår på kroppen, som er anderledes end din psoriasis.
English: Overall skin disease
Danish: Overordnet hudsygdom
English: Always use this medicine exactly as your doctor or nurse has told you.
Danish: Brug altid lægemidlet nøjagtigt efter lægens eller sundhedspersonalets anvisning.
English: Guselkumab was superior to secukinumab as measured by the primary endpoint of PASI 90 response at Week 48 (84.5% versus 70.0%, p < 0.001).
Danish: Guselkumab var bedre end secukinumab målt på det primære endepunkt PASI 90-respons i uge 48 (84,5 % versus 70,0 %, p < 0,001).
English: PASI 75 response at Week 12
Danish: PASI 75-respons i uge 12
English: In VOYAGE 2, patients randomised to guselkumab at Week 0 who were Psoriasis Area and Severity Index (PASI) 90 responders at Week 28 were re-randomised to either continue treatment with guselkumab q8w (maintenance treatment) or receive placebo (withdrawal treatment).
Danish: I VOYAGE 2 blev de patienter, der blev randomiseret til guselkumab i uge 0, som var PASI 90respondere (Psoriasis Area and Severity Index) i uge 28, randomiseret igen til enten at fortsætte behandling med guselkumab hver 8. uge (vedligeholdelsesbehandling) eller at få placebo (seponeringsbehandling).
English: Guselkumab demonstrated superiority compared to adalimumab for scalp and hand and foot psoriasis at Week 24 (VOYAGE 1 and 2) and Week 48 (VOYAGE 1) (p ≤ 0.001, except for hand and foot psoriasis at Week 24 [VOYAGE 2] and Week 48 [VOYAGE 1], p < 0.05).
Danish: Guselkumab var bedre end adalimumab for så vidt angår psoriasis i hovedbund samt på hænder og fødder i uge 24 (VOYAGE 1 og 2) og uge 48 (VOYAGE 1) (p ≤ 0,001, med undtagelse af psoriasis på hænder og fødder i uge 24 [VOYAGE 2] og uge 48 [VOYAGE 1], p < 0,05).
English: Baseline disease characteristics were consistent for the study populations in VOYAGE 1 and 2 with a median body surface area (BSA) of 22% and 24%, a median baseline PASI score of 19 for both studies, a median baseline dermatology quality of life index (DLQI) score of 14 and 14.5, a baseline investigator global assessment (IGA) score of severe for 25% and 23% of patients, and a history of psoriatic arthritis for 19% and 18% of patients, respectively.
Danish: Sygdomskarakteristika ved baseline svarede til hinanden for undersøgelsespopulationerne i VOYAGE 1 og 2, med et mediant legemsoverfladeareal (BSA) på henholdsvis 22 % og 24 %, en median PASI-score ved baseline på 19 for begge studier, en median score for indeks for dermatologisk livskvalitet (DLQI) ved baseline på henholdsvis 14 og 14,5, en score for Investigator Global Assessment (IGA) ved baseline på svær for henholdsvis 25 % og 23 % af patienterne samt psoriasisartrit i anamnesen for henholdsvis 19 % og 18 % af patienterne.
English: No new safety findings were observed in patients who switched from ustekinumab to guselkumab.
Danish: Der blev ikke observeret nogen nye sikkerhedsmæssige aspekter hos patienter, som skiftede fra ustekinumab til guselkumab.
English: The systemic exposure of guselkumab (Cmax and AUC) increased in an approximately dose-proportional manner following a single subcutaneous injection at doses ranging from 10 mg to 300 mg in healthy subjects or patients with plaque psoriasis.
Danish: Den systemiske eksponering for guselkumab (Cmax og AUC) steg på en tilnærmelsesvis dosisproportional måde efter en enkelt subkutan injektion ved doser fra 10 mg/kg til 300 mg/kg hos raske forsøgspersoner eller patienter med plaque-psoriasis.
English: Week 76
Danish: Uge 76
English: Tremfya can potentially cause serious side effects, including allergic reactions and infections.
Danish: Vær opmærksom på infektioner og allergiske reaktioner Tremfya kan potentielt give alvorlige bivirkninger, herunder allergiske reaktioner og infektioner.
English: EU/1/17/1234/003 (2 packs, each containing 1 pre-filled pen)
Danish: EU/1/17/1234/003 (2 pakninger, der hver indeholder 1 fyldt pen)
English: For patients randomised to adalimumab at Week 0 who crossed over to guselkumab at Week 52, the PASI 90 response rate increased from Week 52 through Week 76 and was then maintained through Week 156 (see Figure 2).
Danish: Hos patienter, som blev randomiseret til adalimumab i uge 0, og som overgik til guselkumab i uge 52, steg PASI 90-responsraten fra uge 52 til og med uge 76 og blev derefter opretholdt til og med uge 156 (se figur 2).
English: No new safety findings were observed in patients who switched from adalimumab to guselkumab.
Danish: Der blev ikke observeret nogen nye sikkerhedsmæssige aspekter hos patienter, som skiftede fra adalimumab til guselkumab.
English: At the start, your doctor or nurse will inject Tremfya.
Danish: I begyndelsen er det lægen eller sundhedspersonalet, der giver injektionen med Tremfya.
English: Summary of Regional Disease Responses in VOYAGE 1 and VOYAGE 2 VOYAGE 1
Danish: Tabel 3: Oversigt over respons for regional sygdom i VOYAGE 1 og VOYAGE 2
English: • The dose is 100 mg (the content of 1 pre-filled syringe) given by injection under the skin
Danish: • Dosis er på 100 mg (indholdet i 1 fyldt injektionssprøjte) givet som injektion under huden
English: Hold syringe body below finger flange.
Danish: Hold på sprøjtecylinderen under fingerkraven.
English: PASI Response Rates in ECLIPSE
Danish: PASI-responsrater i ECLIPSE
English: Do not use this medicine if you notice that the medicine is cloudy or discoloured, or contains large particles.
Danish: Brug ikke lægemidlet, hvis du bemærker, at det er uklart eller misfarvet eller indeholder store partikler.
English: Excipients: sucrose, histidine, histidine monohydrochloride monohydrate, polysorbate 80, water for injections.
Danish: Hjælpestoffer: saccharose, histidin, histidin-monohydrochlorid-monohydrat, polysorbat 80, vand til injektionsvæsker.
English: • Talk to your doctor if you are breast-feeding or are planning to breast-feed.
Danish: • Tal med din læge, hvis du ammer eller planlægger at amme.
English: Summary of Patient Reported Outcomes at Week 16 in VOYAGE 1 and VOYAGE 2 VOYAGE 1
Danish: Tabel 4: Oversigt over patientrapporterede resultater i uge 16 i VOYAGE 1 og VOYAGE 2
English: SINGLE-USE DEVICE
Danish: ANORDNING TIL ENGANGSBRUG
English: Check the expiration date (‘EXP') on the back panel of the carton.
Danish: Kontrollér udløbsdatoen (‘EXP') på kartonens bagside.
English: EU/1/17/1234/004 (2 packs, each containing 1 pre-filled syringe)
Danish: EU/1/17/1234/004 (2 pakninger, der hver indeholder 1 fyldt injektionssprøjte)
English: Prior to initiating therapy with Tremfya, completion of all appropriate immunisations should be considered according to current immunisation guidelines.
Danish: Inden behandling med Tremfya påbegyndes, skal det overvejes at sikre, at patienten har fået alle relevante vaccinationer i henhold til aktuelle retningslinjer for vaccination.
English: - The other ingredients are histidine, histidine monohydrochloride monohydrate, polysorbate 80,
Danish: - Øvrige indholdsstoffer: histidin, histidin-monohydrochlorid-monohydrat, polysorbat 80,
English: If your doctor decides that you or a caregiver may be able to give your injections of Tremfya at home, you should receive training on the right way to prepare and inject Tremfya using the pre-filled syringe before attempting to inject.
Danish: Hvis din læge beslutter, at du eller en plejeperson kan give dig injektionerne med Tremfya derhjemme, skal du have undervisning i, hvordan du klargør og injicerer Tremfya korrekt med den fyldte injektionssprøjte, inden du forsøger at injicere.
English: DLQI, subjects with baseline score
Danish: DLQI, forsøgspersoner med baseline-score
English: Before injection
Danish: Før injektion
English: After your injection
Danish: Efter din injektion
English: This may be given by your doctor or nurse.
Danish: Den gives til dig af lægen eller sundhedspersonalet.
English: Multipack: 2 (2 packs of 1) pre-filled pens
Danish: Multipakning: 2 (2 pakninger med 1) fyldte penne
English: Inject within 5 minutes of removing the cap.
Danish: Injicer senest 5 minutter efter at du har fjernet hætten.